CSIMarket Company Name, Ticker, Industry, else..
 
Aclaris Therapeutics Inc   (NASDAQ: ACRS)
Other Ticker:  
 
 
Price: $1.3400 $0.07 5.512%
Day's High: $1.36 Week Perf: 17.03 %
Day's Low: $ 1.26 30 Day Perf: -21.18 %
Volume (M): 509 52 Wk High: $ 5.17
Volume (M$): $ 682 52 Wk Avg: $1.72
Open: $1.27 52 Wk Low: $0.95



 Market Capitalization (Millions $) 103
 Shares Outstanding (Millions) 77
 Employees 91
 Revenues (TTM) (Millions $) 19
 Net Income (TTM) (Millions $) -132
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 36

Aclaris Therapeutics Inc
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet needs in dermatology and immunology. The company has a diverse pipeline of drug candidates targeting various skin and hair disorders, including alopecia areata, vitiligo, and common warts. Aclaris Therapeutics aims to provide effective and safe treatment options for patients suffering from these medical conditions. The company's research and development efforts are centered on discovering novel compounds and utilizing advanced technologies to improve patient outcomes.


   Company Address: 701 Lee Road, Suite 103 Wayne 19087 PA
   Company Phone Number: 324-7933   Stock Exchange / Ticker: NASDAQ ACRS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        9.33% 
BMY   -2.13%    
JNJ   -1.49%    
LLY        8.22% 
MRK        6.28% 
SNY        3.55% 
• View Complete Report
   



Shares

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Published Mon, Jan 6 2025 9:30 PM UTC

Aclaris Therapeutics: Strategic Inducement Grants Amid Promising Clinical AdvancesOn September 17, 2024, Aclaris Therapeutics Inc. announced the initiation of dual Phase 2a clinical trials for ATI-2138, aiming to address the critical dermatological condition of atopic dermatitis and the gastrointestinal ailment of ulcerative colitis. This significant move signaled the compan...
Clinical Study

Aclaris Therapeutics Launches Dual Phase 2a Trials for ATI-2138, Targeting Atopic Dermatitis and Ulcerative Col...

Published Tue, Sep 17 2024 11:00 AM UTC

Aclaris Therapeutics has recently completed a pivotal step in the journey of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, by dosing the first patient in not one, but two Phase 2a clinical trials. These trials aim to evaluate the efficacy of ATI-2138 in treating moderate to severe atopic dermatitis and moderate to severe ulcerative colitis, respectively. The...
Aclaris Therapeutics Inc

Major Pharmaceutical Preparations Company Reports Loss of $-0.24 per Share in Fiscal First Quarter 2024

As a prominent player in the healthcare sector, Aclaris Therapeutics Inc has recently announced significant leadership changes and a strategic business review. These developments come on the heels of a period of financial underperformance for the company, with a net loss of $115 million reported for the twelve months leading up to the third quarter of 2023. With a negative return on assets (ROA) of -48.43%, it is clear that Aclaris Therapeutics is facing significant challenges.
One of the most notable changes within Aclaris Therapeutics is the transition in leadership. Douglas Manion, M.D., who served as the Chief Executive Officer, President, and Member of the Board of Directors, has stepped down. Dr. Manion was at the helm of the company during a period of financial struggles, and his departure presents an opportunity for Aclaris Therapeutics to bring in fresh perspectives and operational strategies.
Aclaris Therapeutics Inc

2. Aclaris Therapeutics Inc: Paving the Way for Innovative Healthcare Solutions

The strategic business review initiated by Aclaris Therapeutics aims to identify areas of improvement and optimize its resources to drive growth and create value for shareholders. The company is focused on leveraging its expertise in developing drug candidates for immuno-inflammatory diseases to capitalize on emerging opportunities in the healthcare market. With a strong pipeline of innovative products, Aclaris Therapeutics is well-positioned to address unmet medical needs and enhance patient outcomes.
Despite the recent financial challenges, Aclaris Therapeutics remains committed to advancing its mission of delivering groundbreaking therapies to patients in need. The company's dedication to research and development underscores its long-term vision for sustainable growth and success in the pharmaceutical industry. By investing in innovative healthcare solutions, Aclaris Therapeutics aims to expand its market presence and solidify its reputation as a leading provider of pharmaceutical preparations.
Management Changes

Aclaris Therapeutics: Charting a Path to Financial Reinvention and Leadership Reinforcement

Published Tue, Jan 16 2024 12:01 PM UTC



Aclaris Therapeutics, a prominent player in the healthcare sector, has recently announced significant leadership changes and a strategic business review. The decision comes after a period of financial underperformance, with the company s year-to-date stock performance showing a decline of 12%. Additionally, Aclaris Therapeutics reported a net loss of $115 million f...






Aclaris Therapeutics Inc's Segments
Therapeutics Segment    85.16 % of total Revenue
Contract Research Segment    69.83 % of total Revenue
Corporate and Other    -69.83 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com